Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

    Research output: Contribution to journalReviewResearchpeer-review

  2. Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cyclosporine and COVID-19: Risk or favorable?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Longitudinal Increases in Serum Insulin-like Factor 3 and Testosterone Determined by LC-MS/MS in Pubertal Danish Boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Marked increase in incident gynecomastia: a 20-year national registry study, 1998 to 2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Marked Increase in Incident Gynecomastia: A 20-Year National Registry Study, 1998 to 2017

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Testicular germ cell tumors (TGCTs) are classified as either seminomas or nonseminomas. Both tumors originate from carcinoma in situ (CIS) cells, which are derived from transformed fetal gonocytes. CIS, seminoma, and the undifferentiated embryonal carcinoma (EC) retain an embryonic phenotype and express pluripotency factors (NANOG/OCT4). Vitamin D (VD) is metabolized in the testes, and here, we examined VD metabolism in TGCT differentiation and pluripotency regulation. We established that the VD receptor (VDR) and VD-metabolizing enzymes are expressed in human fetal germ cells, CIS, and invasive TGCTs. VD metabolism diminished markedly during the malignant transformation from CIS to EC but was reestablished in differentiated components of nonseminomas, distinguished by coexpression of mesodermal markers and loss of OCT4. Subsequent in vitro studies confirmed that 1,25(OH)(2)D(3) (active VD) downregulated NANOG and OCT4 through genomic VDR activation in EC-derived NTera2 cells and, to a lesser extent, in seminoma-derived TCam-2 cells, and up-regulated brachyury, SNAI1, osteocalcin, osteopontin, and fibroblast growth factor 23. To test for a possible therapeutic effect in vivo, NTera2 cells were xenografted into nude mice and treated with 1,25(OH)(2)D(3), which induced down-regulation of pluripotency factors but caused no significant reduction of tumor growth. During NTera2 tumor formation, down-regulation of VDR was observed, resulting in limited responsiveness to cholecalciferol and 1,25(OH)(2)D(3) treatment in vivo. These novel findings show that VD metabolism is involved in the mesodermal transition during differentiation of cancer cells with embryonic stem cell characteristics, which points to a function for VD during early embryonic development and possibly in the pathogenesis of TGCTs.
Original languageEnglish
JournalNeoplasia
Volume14
Issue number10
Pages (from-to)952-63
Number of pages12
ISSN1522-8002
Publication statusPublished - 2012

ID: 36806314